Long-term use of bevacizumab for the treatment of age-related macular degeneration: safety
CADTH
Record ID 32015000197
English
Authors' recommendations:
One systematic review and two randomized controlled trials were identified regarding the long-term safety (at least 2 years) of bevacizumab for the treatment of age-related macular degeneration.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.cadth.ca/media/pdf/htis/dec-2014/RB0717%20Long%20Term%20Safety%20of%20Bevacizumab%20Final.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Intravitreal Injections
- Angiogenesis Inhibitors
- Antibodies, Monoclonal, Humanized
- Drug Therapy, Combination
- Time Factors
- Treatment Outcome
- Visual Acuity
- Vascular Endothelial Growth Factor A
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.